A5088023899- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Acute Myeloid Leukemia Research
- Lymphoma Diagnosis and Treatment
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Cancer-related gene regulation
- Peptidase Inhibition and Analysis
- Immune cells in cancer
- Cancer Mechanisms and Therapy
- Reproductive System and Pregnancy
- Ubiquitin and proteasome pathways
- HIV/AIDS drug development and treatment
- Sinusitis and nasal conditions
- Chronic Myeloid Leukemia Treatments
- Salivary Gland Tumors Diagnosis and Treatment
- Infectious Diseases and Mycology
- PI3K/AKT/mTOR signaling in cancer
- Chronic Lymphocytic Leukemia Research
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Autoimmune Neurological Disorders and Treatments
- Antifungal resistance and susceptibility
- Acute Lymphoblastic Leukemia research
- Hemoglobinopathies and Related Disorders
- Pneumocystis jirovecii pneumonia detection and treatment
- Extracellular vesicles in disease
Kyoto Prefectural University of Medicine
2020-2024
Walter and Eliza Hall Institute of Medical Research
2023
Kyoto first Red Cross hospital
2022
This study retrospectively aimed to assess the real-world efficacy and safety of polatuzumab vedotin with bendamustine rituximab for relapsed/refractory diffuse large B-cell lymphoma, analyzing 72 patients within Kyoto Hematology Clinical Study Group. The median age was 77, one-third participants over 80 half having previously received three or more lines treatment. overall response rate 73.6%, including 45.8% complete response. progression-free survival (PFS) 7.6 months. Poor performance...
The shift of the tumour immune microenvironment to a suppressive state promotes not only development and progression disease in multiple myeloma (MM) but also resistance immunotherapy. We previously demonstrated that cells can induce monocytic myeloid-derived suppressor (M-MDSCs) from healthy peripheral blood mononuclear (PBMCs) via concomitant secretion CC motif chemokine ligand 5 (CCL5) macrophage migration inhibitory factor (MIF), an unknown mediator M-MDSC induction. This study...
B-cell lymphomas (BCLs) are the most common disease entity among hematological malignancies and have various genetically molecularly distinct subtypes. In this study, we revealed that blockade of phosphoinositide-dependent kinase-1 (PDPK1), master kinase AGC kinases, induces a growth inhibition via cell cycle arrest induction apoptosis in all eight BCL-derived lines examined, including those from activated B-cell-like diffuse large lymphoma (DLBCL), double expressor DLBCL, Burkitt lymphoma,...
Abstract RSK2 is a serine/threonine kinase downstream signaling mediator in the RAS/ERK pathway and may be therapeutic target mantle cell lymphoma (MCL), an almost incurable disease subtype of non‐Hodgkin lymphoma. In this study, serine‐227 (RSK2 Ser227 ) N‐terminal domain (NTKD) was found to ubiquitously active five MCL‐derived lines tumor tissues derived from MCL patients. BI‐D1870, inhibitor specific RSK2‐NTKD, caused dephosphorylation, thereby, induced dose‐dependent growth inhibition...
Abstract Background Combinatory strategies with carfilzomib (CFZ), a second‐generation proteasome inhibitor, plus dexamethasone (DEX) or without lenalidomide (LEN) have shown promising efficacy for patients relapsed/refractory multiple myeloma (RRMM) in pivotal clinical trials. However, their effects on who were resistance to bortezomib (BTZ) and/or LEN not been fully evaluated daily practice setting. Aims To evaluate the real‐world and safety of CFZ‐based treatments; that is, CFZ DEX (KRD...
Multiple myeloma (MM) is characterized by remarkable cytogenetic/molecular heterogeneity among patients and intraclonal diversity even in a single patient. We previously demonstrated that PDPK1, the master kinase of series AGC kinases, universally active MM, plays pivotal roles cell proliferation survival cells regardless profiles cytogenetic genetic abnormalities. This study investigated therapeutic efficacy mechanism action dual blockade two major PDPK1 substrates, RSK2 AKT, MM. The...
Invasive fungal rhinosinusitis (FRS) is a rare but intractable infectious disease of the sinonasal region with destructive direct infiltration into surrounding tissues, such as bone, orbit and brain, potential dissemination to systemic organs. Symptomatic assessments imaging are frequently not sufficiently diagnostic, histopathological examination essential for definite diagnosis FRS. We herein report case chronic invasive FRS (CIFRS) in 58-year-old Japanese male end-stage diabetic...
Abstract B‐cell receptor (BCR) signaling is critically activated and stable for mantle cell lymphoma (MCL), but the underlying mechanism of BCR pathway not clear. The pathogenic basis miR‐17‐92 cluster remains unclear although oncogenic microRNA (miRNA) highly expressed in patients with MCL. We revealed that overexpression partly dependent on SOX11 expression chromatin acetylation MIR17HG enhancer regions. Moreover, regulates only proliferation activation MCL lines. To comprehensively...
Good's syndrome is a pathologic condition characterized by thymoma and immunoglobulin disorder. Here, we report rare case of patient with simultaneous pure red cell aplasia (PRCA) subclinical myasthenia gravis detectable serum anti-acetylcholine receptor antibody (AChR Ab). While thymectomy did not result in the improvement any paraneoplastic syndromes, cyclosporine A (CsA) treatment successfully improved PRCA; however, hypoglobulinemia was recovered, anti-AchR Ab disappear CsA our case....
Carfilzomib (CFZ) constitutes powerful combinatory therapy for relapsed/refractory multiple myeloma (RRMM); however, cardiovascular adverse events (CVAEs) have been shown as major treatment obstacles with the use of CFZ. Along our multi-institutional prospective observational study by Kyoto Clinical Hematology Study Group on efficacy and safety CFZ-based treatments (UMIN000025108), we here performed an ad hoc analysis CFZ-related CVAEs in 50 patients RRMM. We analyzed association between...
Abstract B-cell receptor (BCR) signaling is critically activated and targetable for mantle cell lymphoma (MCL); however, the underlying mechanism of BCR pathway not clear. The pathogenic basis miR-17-92 cluster remains unclear although oncogenic microRNA (miRNA) highly expressed in patients with MCL. This study revealed that overexpression partly dependent on SOX11 expression chromatin acetylation MIR17HG enhancer regions. Moreover, regulates only proliferation but activation MCL lines....
Topic: 20. Lymphoma Biology & Translational Research Background: B-cell receptor (BCR) signaling is highly activated and a bona fide therapeutic target in mantle cell lymphoma (MCL), whereas the mechanism underlying BCR activation has not been fully understood. MicroRNA (miRNA) miR-17-92 cluster, containing miR-17, miR-18a, miR-19a, miR-19b, miR-20a, miR-92a, acts as an oncogene shown to be upregulated MCL; however, function molecules of each miRNA have remained clarified. These provoked us...
Azacitidine (AZA) has been one of the standard treatments for transplantation‑ineligible patients with myelodysplastic syndrome (MDS); however, hematological toxicities frequently cause treatment interruption in early phase therapy. The present study conducted a multicenter retrospective to investigate prognostic impacts various factors, including factors included Revised International Prognostic Scoring System (IPSS‑R) and severe cytopenia AZA monotherapy 212 MDS. Severe was evaluated after...